Earnings | AstraZeneca Pharma India Ltd. (NSE:ASTRAZEN): Q3FY23 Results Out; Total Income rise 25% YoY

AstraZeneca Pharma India Ltd. (NSE:ASTRAZEN) is a leading biopharmaceutical company that operates in India. The company manufactures and markets prescription drugs for a wide range of therapeutic areas, including cardiovascular, respiratory, neuroscience, and oncology. They also offer a range of innovative and specialty medicines, including biologics and biosimilars. With a strong focus on research and development, AstraZeneca Pharma India Ltd. is committed to improving patient outcomes and addressing unmet medical needs. The company is a subsidiary of AstraZeneca, a global pharmaceutical company headquartered in the United Kingdom.

AstraZeneca Pharma India Ltd. reported a total income of Rs. 257.0046 crores for the period ended December 31, 2022, compared to Rs. 242.9211 crores for the period ended September 30, 2022. The company’s net profit for the same period was Rs. 29.3044 crores, a decrease from the net profit of Rs. 32.5643 crores reported for the previous period. However, the company’s total income for the period ended December 31, 2022, showed an increase from the same period in the previous year, with Rs. 257.0046 crores reported compared to Rs. 205.8678 crores in 2021. Similarly, the net profit for the same period also increased, with Rs. 29.3044 crores reported compared to Rs. 11.4192 crores in 2021. In terms of earnings per share (EPS), AstraZeneca Pharma India Ltd. reported an EPS of Rs. 11.72 for the period ended December 31, 2022, compared to Rs. 13.03 for the period ended September 30, 2022. The EPS for the same period in the previous year was Rs. 4.57.

For the 9 Months period ended December 31, 2022, the company reported a total income of Rs. 738.3719 crores, an increase from Rs. 584.7105 crores reported during the same period in the previous year. The company’s net profit for the 9 Months period ended December 31, 2022, was Rs. 82.0213 crores, an increase from Rs. 33.8096 crores reported during the same period in the previous year. The EPS for the 9 Months period ended December 31, 2022, was Rs. 32.81, an increase from Rs. 13.44 reported during the same period in the previous year.

Overall, while the company’s net profit for the period ended December 31, 2022, decreased compared to the previous period, it showed an increase compared to the same period in the previous year. The company’s total income and EPS also showed an increase for the same period.